A securities class action lawsuit has been filed against Organon & Co., a healthcare company based in Jersey City, NJ, on behalf of investors who purchased Organon securities between October 31, 2024, and April 30, 2025. The lawsuit alleges that despite the company's assurances to maintain its dividend following its $1.2 billion acquisition of Dermavant, Organon shifted its capital allocation focus to debt reduction. Investors have until July 22, 2025, to seek appointment as lead plaintiff in the case. Berger Montague PC, a firm with a long history in securities litigation, is handling the case. Organon is noted for its focus on women's health and dermatological conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。